Myelodysplastic Syndromes

Latest News

MDS | Image Credit: © ibreakstock-stock.adobe.com
Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

December 11th 2024

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.

Visualization of myelodysplastic syndromes | image credit: Lily - stock.adobe.com
Additional Hematopoietic Malignancy Predispositions Accounted for in Updated Surveillance Recommendations

December 11th 2024

Child in hospital looking out window | Image credit: MIA Studio - stock.adobe.com
Survivors of Childhood Cancer at 9-Fold Greater Risk for Late Subsequent Leukemia 

November 29th 2024

MDS wooden blocks held by hand in glove | Image Credit: © Sviatlana - stock.adobe.com
Venetoclax May Be an Option for Children With R/R AML, MDS

November 27th 2024

Pediatrician test results tablet parent child | Image Credit: © nimito - stock.adobe.com
Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

November 11th 2024

More News

data on screen representing a clinical trial
August 7th 2023

Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

Chris Ryan
The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.
Garcia-Mareno
July 29th 2023

Annual Clinical Update on MDS Sees Hope in Precision Medicine, Use of Oral Therapy

Mary Caffrey
An overview of the 2023 recommendations on myelodysplastic syndromes by Guillermo Garcia-Mareno, MD, of MD Anderson Cancer Center, appears in the August issue of the American Journal of Hematology.
Clinical trial
July 27th 2023

Investigators Discontinue Trial Assessing Magrolimab Combo in Higher-Risk MDS

Russ Conroy
Investigators will submit data from the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk myelodysplastic syndromes for presentation at a future medical meeting.
Blood in Test Tubes
July 19th 2023

Common CVD Biomarkers May Hold Prognostic Value in MDS, Study Finds

Rose McNulty
The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.
Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
July 14th 2023

Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma

Rose McNulty
The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
Elsa Bernard, PhD
July 7th 2023

Validating a New Scoring System in MDS for the Era of Next-Generation Sequencing

Mary Caffrey
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data.
Image of molecular profiling
December 25th 2022

Distinct Molecular Profiles in Younger vs Older Patients With MDS Identified in New Study

Rose McNulty
The relationship between aging and molecular profiles in myelodysplastic syndromes (MDS) is not well understood, but the findings suggest that different genetic alterations have distinct prognostic implications in different age groups.
blood cells floating around
December 22nd 2022

ICYMI: Top Content From EHA22

AJMC Staff
The 2022 European Hematology Association (EHA22) Congress convened June 9-12, 2022, in Vienna, Austria, and presented cutting-edge findings in hematology, including the potential of artificial intelligence, new treatment combinations in myelofibrosis, and more.
genetic mutations
December 18th 2022

ASXL1 Mutations Associated With Worse Prognosis in MDS and AML

Rose McNulty
A recent meta-analysis found ASXL1 mutations to be independent risk factors for worse overall survival and transformation to acute myeloid leukemia in patients with myelodysplastic syndromes (MDS), as well as worse overall survival in acute myeloid leukemia (AML).
patient with mds
December 12th 2022

Study Identifies Sex-Related Differences in MDS Phenotypes, Genotypes, and Outcomes

Rose McNulty
Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).
blood test
December 9th 2022

Phase 3 Trials in High-Risk MDS Highlight Future Directions

Rose McNulty
A recent review emphasizes a need for novel therapies, summarizes current phase 3 clinical trials, and suggests several considerations for future trials in high-risk myelodysplastic syndromes (MDS).
Unmet Needs in Management of Patients With MDS
November 8th 2022

Unmet Needs in Management of Patients With MDS

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.
Cost-Reduction Strategies in MDS Treatment Pathway
November 8th 2022

Cost-Reduction Strategies in MDS Treatment Pathway

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.
Oral Therapies in MDS Treatment Strategy
November 1st 2022

Oral Therapies in MDS Treatment Strategy

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.
Utilizing Care Pathways in Treatment of MDS
November 1st 2022

Utilizing Care Pathways in Treatment of MDS

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.
Payer Considerations for Selecting Optimal MDS Treatment Approach
October 25th 2022

Payer Considerations for Selecting Optimal MDS Treatment Approach

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.
Hypomethylating Agents Impacting MDS Treatment Landscape
October 25th 2022

Hypomethylating Agents Impacting MDS Treatment Landscape

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.
Supportive Care Needs for Patients with MDS
October 18th 2022

Supportive Care Needs for Patients with MDS

Experts discuss the impact of supportive care in the MDS treatment landscape.
Assessing Treatment Goals for Patients with MDS
October 18th 2022

Assessing Treatment Goals for Patients with MDS

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.
Drivers of Health Resource Management in MDS
October 11th 2022

Drivers of Health Resource Management in MDS

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Challenges Surrounding Access to Care for Patients With MDS
October 11th 2022

Challenges Surrounding Access to Care for Patients With MDS

Expert panelists explore challenges impacting care access for patients with MDS.
Prognostic Models Optimizing MDS Treatment Pathways
October 4th 2022

Prognostic Models Optimizing MDS Treatment Pathways

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.
Incidence and Prevalence of MDS Across Patient Populations
October 4th 2022

Incidence and Prevalence of MDS Across Patient Populations

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.
MDS Impacting Patient Quality of Life
September 27th 2022

MDS Impacting Patient Quality of Life

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
September 27th 2022

Defining Myelodysplastic Syndrome

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Elli Papaemmanuil, PhD.
June 30th 2022

Dr Elli Papaemmanuil Discusses Molecular Profiling of MDS, Use of Precision Medicine

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.
Elli Papaemmanuil, PhD.
June 12th 2022

Dr Elli Papaemmanuil Explains Novel Prognostication, Molecular Classification System for MDS

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.
Expert on MDS
February 7th 2022

Future Management of Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
Expert on MDS
February 7th 2022

Interchangeability Between Oral and IV Agents in HR-MDS

Bruce Feinberg, DO Ryan Haumschild, PharmD, MS, MBA Amer Zeidan, MD Tracey Iraca
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
Expert on MDS
January 31st 2022

Oral Therapy for HR-MDS: Addressing Patient Adherence

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo